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INTRODUCTION
Tumor necrosis factor-α (TNF-α) is a
key regulator of the inflammatory cas-
cade in rheumatoid arthritis (RA) and
several other inflammatory diseases
(1–3). To date, three TNF antagonists, in-
fliximab (Remicade), etanercept (Enbrel),
and adalimumab (Humira), have been
approved by the FDA to treat RA and
other inflammatory diseases. The molec-
ular mechanisms for these three TNF in-
hibitors are similar: they block the bind-
ing of TNF-α to its cell-surface receptors
and limit subsequent cell signaling path-
ways that are induced or regulated by
TNF-α. Etanercept is a dimeric TNF
receptor-IgG fusion protein and mimics
the inhibition effects of soluble TNF re-
ceptor by binding to TNF-α. Infliximab
is a chimeric mouse-human antibody,
while adalimumab is a fully humanized
antibody.
Although the therapeutic utility of
TNF-α antagonism is well established, pa-
tients display substantial heterogeneity in
their response to anti-TNF therapies, and
the efficacy of any anti-TNF agent in a
given patient is unpredictable. Approxi-
mately one-third of patients have minimal
or no response to these agents (4). A ge-
netic influence has been suggested based
on candidate gene studies (5,6), but no
comprehensive analysis of this issue has
been reported. In a recent review, Coenen
et al. (7) summarized 17 pharmacogenetic
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The prediction of response (or non-response) to anti-TNF treatment for rheumatoid arthritis (RA) is a pressing clinical problem.
We conducted a genome-wide association study using the Illumina HapMap300 SNP chip on 89 RA patients prospectively fol-
lowed after beginning anti-TNF therapy as part of Autoimmune Biomarkers Collaborative Network (ABCoN [Autoimmune Bio-
markers Collaborative Network]) patient cohort. Response to therapy was determined by the change in Disease Activity Score
(DAS28) observed after 14 wks. We used a two-part analysis that treated the change in DAS28 as a continuous trait and then
incorporated it into a dichotomous trait of “good responder” and “nonresponder” by European League Against Rheumatism
(EULAR) criteria.We corrected for multiple tests by permutation, and adjusted for potential population stratification using EIGEN-
STRAT. Multiple single nucleotide polymorphism (SNP) markers showed significant associations near or within loci including: the
v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (MAFB) gene on chromosome 20; the type I interferon gene
IFNk on chromosome 9; and in a locus on chromosome 7 that includes the paraoxonase I (PON1) gene. An SNP in the IL10 pro-
moter (rs1800896) that was previously reported as associated with anti-TNF response was weakly associated with response in
this cohort. Replications of these results in independent and larger data sets clearly are required. We provide a reference list of
candidate SNPs (P < 0.01) that can be investigated in future pharmacogenomic studies.
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studies of anti-TNF treatment that were
conducted after 2001. All of the 17 studies
focused on polymorphisms in genes
known to be involved in RA pathogene-
sis, genes encoding TNF-α receptors, or
genes implicated in TNF-α metabolism.
Several groups reported that a single nu-
cleotide polymorphism (SNP), –308G > A,
in the promoter of TNFA is associated sig-
nificantly with the outcome to anti-TNF
treatment (5,8–14). This positive associa-
tion also is supported by a meta-analysis
that was performed using 311 patients
combined from several studies (13).
To identify biomarkers influencing re-
sponse to anti-TNF therapy, the Autoim-
mune Biomarkers Collaborative Network
(ABCoN) has prospectively enrolled a
cohort of RA patients beginning anti-
TNF treatment. Using these patient sam-
ples, we took an unbiased genome-wide
approach to finding common genetic
variations that could be responsible for
individual differences in response to the
three anti-TNF agents. We report results
for SNPs with lowest P values from the
GWA study, and provide details for se-
lected candidate genes.
MATERIALS AND METHODS
Patients
The Autoimmune Biomarkers Collabo-
rative Network (ABCoN) was estab-
lished to explore the use of new tech-
nologies for biomarker discovery in both
RA and Systemic Lupus (SLE). The
ABCoN RA cohort includes 116 active
RA patients followed prospectively to
evaluate efficacy of the three available
anti-TNF agents. To examine the re-
sponse to anti-TNF therapy in RA, blood
samples, laboratory data, and clinical
data were collected at baseline (prior to
anti-TNF therapy), 6 wks, 3 months,
6 months, and 1 year post treatment.
DNA, RNA, peripheral blood cells,
plasma, serum, and urine were obtained
at the time of each study visit. Enroll-
ment criteria included having a mini-
mum of six swollen joints at enrollment,
and no previous exposure to anti-TNF
agents during the 6 months prior to en-
rollment in the study. We did not enroll
patients taking more than 10 mg of oral
steroid therapy per d at the time of en-
rollment. All the patients provided writ-
ten informed consent. The study proto-
cols were approved by local ethics
committees.
Efficacy Measurements
Disease severity was evaluated using
the DAS28 score, which is the Disease
Activity Score that includes 28-joint
counts and C-reactive protein (15).
DAS28 was measured at three time
points: baseline, 6 wks, and 14 wks. Two
scales were considered to evaluate effi-
cacy of anti-TNF treatment. First, a rela-
tive improvement in disease activity was
calculated for each patient using the
DAS28 scores at baseline and at wk 14:
.
RelDAS28 has a continuous scale and
is approximately normal. Second, accord-
ing to the EULAR definition published
elsewhere (16), patients are classified as
good, moderate, or non-responders,
using the individual amount of change
in the DAS28 (ΔDAS28) and DAS28 val-
ues at 14 wks (16). Briefly, a good re-
sponder is classified if ΔDAS28 ≥ 1.2 and
DAS28 at 14 wks ≤ 3.2; a moderate re-
sponders are patients with (ΔDAS28 ≥
1.2 and DAS28 at 14 wks > 3.2) or 
(0.6 < ΔDAS28 ≤ 1.2 and DAS28 at
14 wks ≤ 5.1). Patients are classified as
non-responders if they do not fall into
any of these categories (16).
Genotyping and Quality Control
The patients’ genomic DNA was ex-
tracted from peripheral blood using stan-
dard protocols. We genotyped 317,000
Single Nucleotide Polymorphisms
(SNPs) on 102 anti-TNF-treated patients
using an Illumina Beadstation and Illu-
mina HAP300 chips according to the
Illumina Infinium 2 assay manual (Illu-
mina, San Diego, CA, USA), as described
previously (17). The HAP300 chip in-
cludes, on average, one SNP every 10
kilobases across all the autosomes, and
interrogates approximately 87% of the
common genetic variation in populations
of European descent (18).
To ensure SNP marker quality and re-
duce the possibility of false associations,
quality control procedures were per-
formed on each of the 317k SNPs before
association tests were carried out. The
SNP set was filtered on the basis of geno-
type call rates (≥ 95%), and minor allele
frequency (MAF ≥ 0.05). Hardy–Weinberg
equilibrium (HWE) was calculated for
individual SNPs using an exact test. All
of the SNPs reported in this manuscript
have HWE P values > 0.001. After filter-
ing, 283,348 polymorphic SNPs were an-
alyzed on chromosome 1 through chro-
mosome 22. The average call rate for the
filtered SNPs was 99.5%. We removed
patients if their percentage of missing
genotypes was more than 5% or if there
was evidence of possible contamination
in their DNA sample.
Statistical Analysis
We evaluated associations between
SNP markers and response to the anti-
TNF therapies in two stages. In the first
stage of our analysis, we used relDAS28
as a continuous dependent variable to
evaluate the associations. Because the
sample size is relatively small in our
study, a continuous scale of the depen-
dent variable has more power than a cat-
egorized variable. Linear regression was
carried out to evaluate association be-
tween individual SNP markers and re-
sponse to anti-TNF therapies (that is, rel-
DAS28) in the context of additive genetic
effect model. A t statistic was derived
from regression and used to evaluate as-
sociation between individual SNP mark-
ers and response to anti-TNF therapies
(that is, relDAS28). The t statistic is ro-
bust, and, thus, some departure from
normality for the dependent variable is
acceptable. Because more than 283,348
tests were involved in this study, a per-
mutation test was carried out to account
for multiple testing on each chromo-
some. The permutation test also can ad-
dress the slight deviation from normality
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in the dependent variable. To obtain ad-
justed P values, the phenotypic values
were shuffled randomly to break the re-
lationship between phenotype and geno-
type. The entire analysis was repeated on
the shuffled data; therefore, the shuffled
data is representative of the null hypoth-
esis. The 1,000 smallest P values were ob-
tained from each of the N = 1,000 permu-
tation iterations for the whole set of
SNPs on individual chromosomes.
In the second stage analysis, we use a
categorized dependent variable–response
status to the anti-TNF therapy (that is,
non-responders versus good responders)
to evaluate association with SNPs se-
lected from the first stage. The probabil-
ity of being a non-responder was mod-
eled using logistic regression with
additive genetic effect model. Unless
specified, all calculations for statistical
analysis were carried out using the
R software package (Version 2.2.1).
Population admixture (that is, sam-
pling of subjects from two or more sub-
populations) has been recognized as a
major cause for inconsistent results and
spurious associations for genetic studies
(19,20). U.S. populations are genetically
admixed. Although self-reported ethnic-
ity data was recorded in this study, it is
incomplete and may be inaccurate. To ac-
curately classify individuals according to
ancestry and to remove any possible re-
lated individuals, we calculated pair-
wise identity-by-state (IBS) distance for
the 102 subjects and performed subse-
quent complete linkage agglomerative
clustering and multidimensional scaling
using genome-wide SNP markers in
Plink software (version 1.00, http://
pngu.mgh.harvard.edu/~purcell/plink/
index.shtml). Clustering data were plot-
ted to identify major population subdivi-
sions. In addition to removing outliers
from the dataset, we further evaluated
potential effect from subpopulations (for
example, northern and southern Euro-
peans) by the EIGENSTRAT program
with genome-wide SNP data (21). The
top ten principal components (PCs) were
obtained. Correlation analysis between
the top PCs and the phenotypes
(delDAS28 and dichotomous response
status to anti-TNF) was performed to de-
tect if the phenotypic difference among
individuals was due to population strati-
fication. If the spread of samples in these
principal components was due purely to
population stratification, it can be re-
moved by forcing all samples to have
zero value in these principal compo-
nents. Then a “virtual” genotype can be
obtained by rotating the corrected princi-
pal components back to the original
genotype space. Pearson′s chi-square
test was performed for association be-
tween selected SNPs and response status
to the anti-TNF therapy (that is, non-
responders versus good responders).
All supplementary materials are available
online at molmed.org.
RESULTS
Among the 102 active RA patients with
complete genotypic and phenotypic data,
self-reported ancestry included 83 Euro-
peans, four Asians, three African Ameri-
cans, as well as three subjects with re-
ported Latino ethnicity. Nine patients
have missing information for their eth-
nicity. Linkage agglomerative clustering
and multidimensional scaling identified
89 patients with primarily European an-
cestry (Supplementary Figure 1), among
them 83 were self-reported to be white
and six had missing ethnicity data. These
89 patients were used for subsequent as-
sociation analysis.
The baseline characteristics of the 89
patients are summarized in Table 1. At the
time of diagnosis, their ages in years were
47 ± 14 (mean ± S.D), their disease dura-
tion was 8 ± 9 years, 75% were women,
and 15% were current smokers. The aver-
age serum CRP level (mg/dl) at baseline
was 1.7 (standard deviation (SD = 2.0). On
average, the DAS28 at the baseline (before
anti-TNF therapy) was 5.22 (SD = 0.80),
indicating that the RA disease activity
was high for most of the patients (16).
Fifty-four subjects were treated with etan-
ercept, 37 with infliximab, and 25 with
adalimumab. These patients had a mean
disease duration of 8 years; 46% had been
treated previously with other DMARDs,
and 7 patients had been treated previ-
ously with TNF inhibitors.
Genome-Wide Association Studies:
First Stage Analysis
The GWA analyses were performed to
test for association between 283,348 poly-
morphic SNPs and the relative change in
DAS28 (relDAS28) using an additive ge-
netic model. We did not adjust the princi-
pal components in our regression model
further, because they did not correlate
significantly with relDAS28 (that is, the
major phenotypic difference among indi-
viduals was not due to population strati-
fication) (Supplementary Table 1). The
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Table 1. Patient Characteristics: European
descent (n = 89)
Age (years) 57 ± 13.5
Age at diagnosis (years) 47 ± 15
Women: (%) 75
Disease duration (years) 8 ± 8
Current Smokers (%) 15
Pain VAS 50.0 ± 22.3
Health VAS 46.4 ± 17.5
Tender (no.) 11.8 ± 6.2
Swollen (no.) 11.2 ± 4.8
HAQ 1.13 ± 0.61
Physician’s global 49.4 ± 19.0
assessment
RF at baseline 238.2 ± 369.6
RF+ % 83.75%a
Serum CRP level (md/dl) 1.7 ± 2.0
at baseline
CCP+ % 61.9%b
DAS 28 at baseline 5.22 ± 0.80
DAS 28 at 6 wk 3.99 ± 1.13
DAS 28 at 14 wk 3.72 ± 1.32
anti-TNF drug
Enbrel n = 39
Humira n = 18
Remicade n = 32
Other Medication
Steroids 63%
Methotrexate 63%
DMARDS 46%
Arava n = 16
Azathioprine n = 1
Sulfasalazine n = 18
Plaquenil n = 15
a11 subjects missing RF data.
b5 subjects missing CCP data.
chromosomal distribution of P values for
the genome-wide association is shown in
Figure 1. To address multiple testing is-
sues, a chromosome-wide permutation
test was performed. Sixteen SNPs remain
significant (permutation exact P ≤ 0.05) or
borderline significant (0.05 < permutation
exact P ≤ 0.1) after permutation test to ob-
tain exact significance levels. The P val-
ues, along with annotation information
for these 16 SNPs, are shown in Table 2.
Among these sixteen SNPs, four are lo-
cated within genes, one is in the 3′UTR,
and eleven are in the flanking regions of
genes. All these SNPs are common poly-
morphisms (minor allele frequency > 0.1).
In addition to Table 2, we also provide
data for 2985 SNPs with relDAS28 P val-
ues ≤ 0.01 in Supplementary Table 1.
We used the Illumina annotation file
“HumanHap317K_geneannotation.txt”
together with the UCSC Genome Browser
to annotate SNP details (22).
Among these leading associations, the
rs6028945 marker ~500 kb 3′ of the
MAFB locus on chromosome 20 is mar-
ginally the strongest association (P =
0.003 corrected) when the relative change
in DAS28 is considered as a continuous
variable; a second marker in the region
of MAFB, rs6071980 also shows evidence
of association (P = 0.05, corrected). Like-
wise, multimarker evidence of associa-
tion is seen with markers in the Paraoxi-
nase 1 gene (PON1) as well as in a region
of chromosome 9 that contains the inter-
feron kappa (IFN-κ), MOBKL2B, and
C9orf72 loci. Other loci showing some
evidence of association include: a guany-
late nucleotide binding protein (GBP6) at
1p22.2; LAG1 (longevity assurance ho-
molog 6, LASS6) at chr2; cystatin D
(CST5) at 20p11.21; centaurin, delta 1
(CENTD1) at 4p14; and quaking ho-
molog and KH domain RNA binding
(QK1) at 6q26-q27 (Table 2).
Association between SNPs and
Response to Anti-TNF Therapy:
Second Stage Analysis
According to the criteria of EULAR
(16), the 89 patients under study can be
categorized into three groups: 23 non-
responders, 31 good responders, and 35
moderate responders using the baseline
DAS28 and the change in DAS28 at 14
wks. We compared allele frequencies be-
tween non-responders and good respon-
ders using the Fisher’s exact test (23).
The last two columns of Table 2 display
Fisher’s exact P values and Odds Ratios
(ORs) with 95% confidence intervals
(CIs) for the non-responder status to the
anti-TNF therapies. Note that these 95%
CIs are very wide, reflecting the small
sample size (that is, 23 non-responders
versus 31 good-responders) in this study.
The major principal components did not
appear to predict good responder versus
nonresponder status (Supplementary
Figure 2). Because the sample size is
quite small (23 non-responders versus 31
responders), a minor effect due to sub-
population may have a large impact on
the 2 × 2 table estimate. Therefore, we
further adjusted subpopulation structure
to give adjusted Chi-square P values
using EIGENSTRAT. As shown in Table 2,
these adjusted Chi-square P values are
generally larger than the Fisher’s exact
test P values.
SNPs in Candidate Genes
Of the markers present on the Illumina
HapMap 300 chip, four SNP associations
with TNF response have been reported
previously in candidate gene studies:
rs1800896 in IL10 (8, 24), rs419598 in in-
terleukin 1 receptor antagonist (IL1RN)
(14), rs1041981 in LTA (25-27), and
rs4149570 in TNFRSF1A (26). These
markers were evaluated separately in
view of their increased prior probability.
In the current study, only rs1800896
shows evidence of association, with a
P value of 0.0132 (uncorrected) with the
delDAS28 and 0.0183 (corrected for strati-
fication only) with responding status to
anti-TNF therapy.
DISCUSSION
In this report, we describe the first ge-
nome-wide association study to evaluate
pharmacogenetic effects on the response
to anti-TNF treatment for rheumatoid
arthritis. Several SNPs show significant
association with the change in DAS28
observed in these patients over a 14-wk
period of treatment.
Two SNPs located approximately 500 kb
downstream of the MAFB (v-maf muscu-
loaponeurotic fibrosarcoma oncogene ho-
molog B) locus show significant evidence
of association after correction by permu-
tation and after accounting for the possi-
ble effects of population stratification.
This gene is a member of the Maf family
of bZIP transcription factors that are in-
volved generally in cellular differentia-
tion (28). MAFB is a putative tumor sup-
pressor in the myeloid lineage, with a
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Figure 1. Genome-wide association P value plots showing the association of single-
nucleotide polymorphism (SNPs) with relative change in DAS28 score (relDAS28). Chromo-
somal location is shown on the abscissa. P values shown on the ordinate are uncorrected.
key role in monopoiesis (29) as well as
monocyte-dendritic cell differentiation
(30). Little is known about the biology of
this gene in the context of inflammatory
disease.
Another interesting association with
anti-TNF response was found in the
paraoxonase (PON1) locus. Paraox-
onase is an enzyme associated with
high density lipoproteins that may play
a role in inflammatory disease (31).
Low serum levels of PON1 have been
reported in inflammatory disorders
(32,33), including rheumatoid arthritis
(34), although, in the setting of autoim-
munity, most attention as been on the
anti-inflammatory effects of PON1 in
risk for cardiovascular disease (35). Ge-
netic regulation of Paraoxonase 1 levels
has been documented (36,37), although
not always by polymorphisms within
PON1 (38). TNF-α, IL6, and PON1 lev-
els appear to be correlated in the setting
of RA (39), although it is certainly not
clear why genetic variation in PON1
should influence response to TNF
inhibition.
Five SNPs in a region of chromosome
9 across a 70-kb region also showed asso-
ciation with treatment response. Of the
three genes in this region with high LD,
IFNκ is the most compelling candidate
for involvement in inflammation and/or
response to anti-TNF treatment, since
type I IFNs clearly play a role in inflam-
matory disease (40).
Only four specific SNPs previously
tested for association with anti-TNF
treatment were included on the 317 K
chip. Of these, we found that the G allele
of rs1800896 (flanking region of IL10) is
associated with good response to anti-
TNF therapies (OR = 2.7 [95% CI:1.2~6.7],
Fisher’s P = 0.0183), which is consistent
with the previous result that the combi-
nation of GG at this locus was associated
with good response to etanercept (8).
One SNP reported to be associated with
response to anti-TNF treatment is
rs1800629, located in the promoter of the
TNF-α gene (7). Neither this SNP nor
perfect surrogates are on the Illumina
317 K array. Thus, our data cannot repli-
cate this previous finding.
As with other previous reports on the
pharmacogenetics of TNF response, this
study is limited by a relatively small
sample size. Therefore, instead of a di-
chotomous classification of patients into
non-responders versus good-responders,
we first utilized the continuous score of
the relative change in DAS28 (that is,
delDAS28) as the dependent variable in a
regression model so that we were able to
utilize all subjects, and, therefore, maxi-
mize the statistical power of the study.
We also performed chromosome-wide
permutation tests to address the issue of
multiple testing. Bonferroni adjustments
often are used in adjusting statistical sig-
nificance for multiple tests. However, the
Bonferroni test is highly conservative,
particularly in the way it tests the overall
null hypothesis, that is, all null hypothe-
ses are true simultaneously (41). Further-
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Table 2. Sixteen SNPs with smallest P values with permutation exact P values ≤ 0.1
Allele 
associated P valueb
with non-responders Odds ratio 
*P valuea Permut. non-response versus (OR) being 
of P value Poly- (allele Physical Known good responders non-responder 
SNP RelDAS28 (RelDAS28) morphism frequency) Chr position genes Locationc (Adjusted)d (95% CI)b
rs983332 0.000005 0.008 A/C A (0.21) 1 87844401 LMO4 F3U 0.00007 (0.00009) 10.2 (2.6, 59.2)
rs928655 0.00003 0.07 A/G A (0.77) 1 89561595 GBP6 I 0.0009 (0.0004) 5.5 (1.8, 20.2)
rs13393173 0.000004 0.02 A/G A (0.12) 2 169214598 LASS6 I 0.004 (0.02) 6.8 (1.7, 40.3)
rs437943 0.000004 0.1 A/G G (0.33) 4 35194664 CENTD1 F3U 0.0007 (0.002) 4.6 (1.8, 12.3)
rs10945919 0.0000003 0.004 A/G G (0.32) 6 164157088 QKI F3U 0.0007 (0.0008) 4.6 (1.8, 12.3)
rs854555 0.000002 0.03 A/C A (0.34) 7 94575042 PON1 I 0.0006 (0.001) 4.6 (1.8, 12.3)
rs854548 0.000003 0.06 A/G A (0.27) 7 94570471 PON1 F3U 0.00004 (0.0003) 8.5 (2.6, 36.5)
rs854547 0.000006 0.1 A/G A (0.63) 7 94568507 PON1 F3U 0.003 (0.004) 3.6 (1.5, 9.3)
rs7046653 0.0000005 0.01 A/G A (0.26) 9 27480967 IFNK F5U 0.0004 (0.002) 4.9 (1.8, 14.0)
rs868856 0.0000005 0.01 C/T T (0.26) 9 27479251 MOBKL2B I 0.0005 (0.002) 4.9 (1.8, 14.0)
rs774359 0.0000006 0.01 C/T C (0.22) 9 27551049 C9orf72 3UTR 0.0005 (0.005) 5.4 (1.9, 17.3)
rs2814707 0.000002 0.04 A/G A (0.22) 9 27526397 MOBKL2B F5U 0.0006 (0.007) 5.2 (1.8, 16.7)
rs3849942 0.000005 0.07 A/G A (0.21) 9 27533281 C9orf72 F3U 0.001 (0.01) 5.0 (1.7, 15.8)
rs6028945 0.0000002 0.003 G/T T (0.12) 20 38254219 MAFB F3U 0.0004 (0.006) 11.2 (2.3, 108.1)
rs6138150 0.000003 0.05 C/T T (0.84) 20 23795009 CST5 F3U 0.0002 (0.002) 11.1 (2.5, 103.3)
rs6071980 0.000003 0.05 C/T C (0.13) 20 38301990 MAFB F3U 0.0009 (0.01) 7.6 (1.9, 44.6)
aThese P values were obtained using the continuous relDAS28 as a dependent variable.
bThese P values or Odds Ratios (95% CI) were obtained from Fisher exact test of 2 × 2 tables of allele frequencies in non-responders versus
good responders.
cF3U: flanking 3′-UTR; F5U: flanking 5′-UTR; I: intron; C: coding; 3UTR: 3′-UTR.
dChi-square P values after adjusting for population substructure in EIGENSTRAT.
more, Bonferroni assumes all tests are in-
dependent, and since there is linkage dis-
equilibrium among some of the SNPs on
the 317K chip, the tests are not truly in-
dependent. Finally, in addition to analyz-
ing the change in DAS28 as a continuous
trait, we classified the patients into three
response groups (that is, non-, moderate,
and good responders) and analyzed as-
sociation to anti-TNF response using the
two extreme groups. The Fisher’s exact
P values for the dichotomous trait are
consistent with the relDAS28 P values in
most circumstances (that is, smaller
Fisher’s exact P values are consistent
with smaller relDAS28 P values).
In addition to choosing the analytical
approach in this analysis carefully, we in-
vestigated sub-population structure in
our study subjects thoroughly to reduce
false positive association that might be
caused by population admixture (19,20).
We calculated IBS estimation and further
performed agglomerative clustering anal-
ysis using the PLINK software to detect
population admixture and strata. We se-
lected 89 subjects with predominantly
European ancestry and performed subse-
quent statistical analyses using only these
subjects. Furthermore, we performed
principal component analysis using the
EIGENSTRAT software to detect possible
minor phenotypic difference in individu-
als due to any subpopulation structure
and provided adjusted Chi-square P val-
ues for selected SNPs in this report.
A further caution regarding these re-
sults relates to the fact that our popula-
tion was rather diverse clinically, with
some patients having quite longstanding
disease and nearly 40% of the patients
were CCP antibody negative; 7 of the 89
patients had previously been treated
with a TNF inhibitor. Therefore, this pop-
ulation is clearly not representative of a
new onset cohort, where information
about TNF responsiveness might be most
clinically useful. Clearly, replications of
these results in independent and much
larger data sets are required to confirm
these findings. Given the fact that so
many patients have been treated with
these agents over the last decade, it is
disappointing that these population re-
sources are not readily available. Never-
theless, several European RA cohorts
may be useful for such replication stud-
ies (7,42). In addition, we, and others, are
actively engaged in an effort to recruit a
United States of America cohort of up to
1,000 RA patients beginning treatment
with TNF inhibitors. Samples sizes of
this magnitude or larger will be required
to provide robust replication of the cur-
rent results.
A test predicting response or non-
response to anti-TNF treatment would be
an important tool in the hands of physi-
cians. TNF inhibitors are currently a
mainstay of biologic therapy in RA.
However, only a fraction of patients
show a clinically meaningful response to
anti-TNF treatment after 3–6 months.
Furthermore, many patients lose re-
sponse over time. After patients fail their
first TNF inhibitor, physicians are faced
with a choice between trying a second
TNF inhibitor or moving to a biologic
therapy with a different mechanism of
action (43). Additional biologic agents
with different mechanisms of action are
available for RA patients who have an
inadequate response to TNF inhibitors
and more potential therapies are in late
phases of clinical development. The abil-
ity to determine whether patients are
likely to be a non-responder to a TNF in-
hibitor would make these treatment deci-
sions more rational. The current results
suggest that this may be achievable.
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